09 February 2024
09 February 2024
The survey by CRO Worldwide Clinical Trials shows that pharma and biotechs favour midsize contract research organisations (CROs) due to the personalised service.
AIM’s Ampligen failed to meet its primary endpoint in the Phase II trial in people with post-Covid fatigue.
In November 2020, the US FDA granted orphan drug designation to AMX0035 to treat WS.
The initiative follows a successful year of unveiling trials in the Asia Pacific region.
TAK-861 was found to be safe and well tolerated without any treatment linked serious adverse events observed.
Digital twin in trials enables TwinRCTs, highly powered studies that have smaller control groups.
AFFINITY data has spurred RegenxBio towards a pivotal study for DMD while pivotal CAMPSIITE data has the company moving towards a biologics licence application (BLA) from the US Food and Drug Administration (FDA).
GSK's antibody-drug conjugate Blenrep recorded sales of $44m in 2023, down significantly from $145m the previous year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
